Clearside Biomedical IncOn the above Weekly chart price action has corrected almost 90% since August 2021. A number of reasons now exist to be bullish , including:
1) A strong buy signal prints (not shown).
2) Regular bullish divergence .
3) Price action confirms support on past resistance.
4) Falling wedge breakout + backtest.
Is it possible price action falls further? Sure.
Is it probable? No.
Ww
Type: trade
Risk: <=6% of portfolio
Timeframe: Don’t know.
Return: Don’t know
Stop loss: <=95 cents
CLSD trade ideas
CLSD LongUptrend Consolidation
SMA200 as support
OBV> OBV34
WR% Crossed -80
Entry 2.47
Stop 2
Target 4.3
Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with small cost.
$CLSDEntry price : 3.80
Fundamentals :
- Sector: Medical - Biotech
- EPS % Chg (Last Qtr): 70%
- EPS % Chg (Previous Qtr): 15%
- 3 Year EPS Growth Rate: 0%
- EPS Est % Chg (Current Yr): 0%
- Sales % Chg (Last Qtr): 2334%
- Sales % Chg (Previous Qtr): 687%
- 3-Year Sales Growth Rate: 265%
- Annual Pre -Tax Margin: -1416%
Clearside Biomedical, Inc. 20% upside Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
CLSD - Triple Bottom. Huge Analyst Prediction Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
Average Recommendation: OVERWEIGHT
Average Target Price: 5.50
SHORT INTEREST
2.26M 07/15/19
P/E Current
-0.48
P/E Ratio (with extraordinary items)
-0.72
CLSD Is this the bottom? End of Elliot 5th Wave + Wyckoff SpringNever have we seen CLSD cross on the weekly RSI to oversold. CLSD made new lows. The more I look at it, the more this looks like a possible bottom as the big picture shows a possible 5th elliot wave + if a possible wyckoff spring. Buy when there is blood on the streets? 2 year hold?
CLSD - Potencial ShortPotencial Short
News - CLSD-News-Wired News – Clearside BioMedical Reported Positive Top-line Results from Phase-3 Trial Assessing CLS-TA in Macular Edema Associated with Non-infectious Uveitis
Volumen 3.5M, Float 18.42M, Avg Vol (10 day) 3.07M, Avg Vol (3 month) 426.32k, NasdaqGM, Healthcare-Biotechnology
Entry 14.25, Stop Loss 14.90, Take profit 12.50, 1D Still green candle# Entry 1m timeframe#Broke trend line#BreakDown#Stock made in 2 days 130%-News (4 News in 2 days-incredible)
Be ready if market make something unpredictable. Stay with your position, carefully!!!
SignalCLSD-Top Gain: 101%- (Clearside Biomedical Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial of CLS-TA in Macular Edema Associated with Non-Infectious Uveitis)-Potential Short
Volumen 8.5M, Float 18.42M, Avg Vol (10 day) 3.07M, Avg Vol (3 month) 426.32k, NasdaqGM, Healthcare-Biotechnology, 1D Red Day
Entry 11.87, Stop Loss 12.15, Take Profit 10
Be ready if market make something unpredictable. Stay with your position, carefully!!!